Albumin-binding prodrugs of auristatin E derivatives

1. A compound having the structure of Formula I or II:

or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof;

wherein:

R′ is H or —CH 3 ,

M is H or a pharmaceutically acceptable counterion;

Y is absent or selected from an optionally substituted C 1 -C 6 alkyl, —NH—C(O)—, —C(O)—NH—, —NH—C(O)—NH—, —C(O)—O—, and —O—C(O)—;

R 1 is absent or an optionally substituted C 1 -C 18 alkyl wherein optionally up to six carbon atoms in said C 1 -C 18 alkyl are each independently replaced with —OCH 2 CH 2 —;

X is H or selected from halogen, —NO 2 , —NR 2 R 3 , —OR 2 , —NHCOR 2 and —OCOR 2 , wherein R 2 and R 3 are each independently selected from H and C 1 -C 4 alkyl;

TBG is a thiol-binding group selected from an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, and an optionally substituted acetylene group.

2. The compound according to claim 1 , wherein R′ is —CH 3 .

3. The compound according to claim 1 , wherein TBG is selected from an optionally substituted maleimide group.

4. The compound according to claim 1 , wherein TBG is a maleimide group of the formula:

5. The compound according to claim 1 , wherein Y is —NH—C(O)—.

6. The compound according to claim 1 , wherein M is H + or Na + .

7. The compound according to claim 1 , wherein R 1 is an optionally substituted C 1 -C 5 alkyl.

8. The compound according to claim 1 , wherein R 1 is C 1 -C 5 alkyl.

9. The compound according to claim 1 , having the structure of Formula III:

10. The compound according to claim 1 , having the structure of Formula IV:

11. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11 , wherein the pharmaceutically acceptable carrier is selected from one or more of a solubilizing agent, an encapsulating agent and a lyoprotectant.

13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier comprises one or more of dimethyl-3-cyclodextrin, hydroxyethyl-3-cyclodextrin, hydroxypropyl-3-cyclodextrin, and trimethyl-3-cyclodextrin.

14. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is suitable for intravenous administration.

15. The pharmaceutical composition of claim 14 , wherein the composition, when administered intravenously to a patient, covalently binds in situ to endogenous albumin in blood circulation.

16. The pharmaceutical composition of claim 15 , wherein the composition, when administered intravenously to a patient, covalently binds in situ to a thiol group of cysteine-34 of endogenous albumin in blood circulation.

17. A method for treating a patient suffering from a disease selected from a cancer, a virus disease, autoimmune disease, acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, and other micro-organisms, comprising administering to the patient a therapeutically effective amount of the compound according to claim 1 or the pharmaceutical composition according to claim 11 .

18. The method of claim 17 , wherein the disease is cancer selected from carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, and melanoma.

19. The method of claim 17 , wherein the administration is intravenous administration.

20. A method of reducing cytotoxicity of a compound comprising administering the compound according to claim 1 or the pharmaceutical composition according to claim 11 to a patient in need thereof, wherein the administration results in a reduction in cytotoxicity when compared to an equivalent dose of unmodified active agent.

21. A method of increasing the concentration of a metabolite of a compound in a tumor, comprising administering the compound according to claim 1 or the pharmaceutical composition according to claim 11 to a patient in need thereof, wherein the increase is compared to an equivalent dose of unmodified active agent.

22. The compound of claim 1 , wherein the compound has a structure of Formula I

23. The compound of claim 1 , wherein the compound has a structure of Formula II

24. The compound of claim 1 , wherein X is selected from the group consisting of F, Cl, Br and I.

25. The compound according to claim 22 , wherein R′ is —CH 3 .

26. The compound according to claim 22 , wherein TBG is selected from an optionally substituted maleimide group.

27. The compound according to claim 22 , wherein TBG is a maleimide group of the formula:

28. The compound according to claim 22 , wherein Y is —NH—C(O)—.

29. The compound according to claim 22 , wherein M is H + or Na + .

30. The compound according to claim 22 , wherein R 1 is an optionally substituted C 1 -C 5 alkyl.

31. The compound according to claim 22 , wherein R 1 is C 1 -C 5 alkyl.

32. The compound according to claim 23 , wherein R′ is —CH 3 .

33. The compound according to claim 23 , wherein TBG is selected from an optionally substituted maleimide group.

34. The compound according to claim 23 , wherein TBG is a maleimide group of the formula:

35. The compound according to claim 23 , wherein Y is —NH—C(O)—.

36. The compound according to claim 23 , wherein M is H + or Na + .

37. The compound according to claim 23 , wherein R 1 is an optionally substituted C 1 -C 5 alkyl.

38. The compound according to claim 23 , wherein R 1 is C 1 -C 5 alkyl.

39. The compound of claim 23 , wherein X is selected from the group consisting of F, Cl, Br and I.

40. A pharmaceutical composition comprising the compound of claim 22 , and a pharmaceutically acceptable carrier.

41. A pharmaceutical composition comprising the compound of claim 23 , and a pharmaceutically acceptable carrier.

42. A method for treating a patient suffering from a disease selected from the group consisting of a cancer, a virus disease, autoimmune disease, acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, and other micro-organisms, comprising administering to the patient a therapeutically effective amount of the compound according to claim 22 or the pharmaceutical composition according to claim 40 .

43. The method of claim 42 , wherein the disease is cancer selected from the group consisting of carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, and melanoma.

44. The method of claim 43 , wherein the cancer is selected from the group consisting of adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma's, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus carcinoma, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinomas, uterine cancer, cervical cancer, neck, nose and ear tumors, hematological neoplasia's, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinoma, craniopharyngeoma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, stomach cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer and lymph gland cancer.

45. A method for treating a patient suffering from a disease selected from the group consisting of a cancer, a virus disease, autoimmune disease, acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, and other micro-organisms, comprising administering to the patient a therapeutically effective amount of the compound according to claim 23 or the pharmaceutical composition according to claim 41 .

46. The method of claim 45 , wherein the disease is cancer selected from the group consisting of carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, and melanoma.

47. The method of claim 46 , wherein the cancer is selected from the group consisting of adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma's, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus carcinoma, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinomas, uterine cancer, cervical cancer, neck, nose and ear tumors, hematological neoplasia's, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinoma, craniopharyngeoma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, stomach cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer and lymph gland cancer.

48. A pharmaceutical composition comprising the compound of claim 9 , and a pharmaceutically acceptable carrier.

49. A pharmaceutical composition comprising the compound of claim 10 , and a pharmaceutically acceptable carrier.

50. A method for treating a patient suffering from a disease selected from the group consisting of a cancer, a virus disease, autoimmune disease, acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, and other micro-organisms, comprising administering to the patient a therapeutically effective amount of the compound according to claim 9 or the pharmaceutical composition according to claim 48 .

51. The method of claim 50 , wherein the disease is cancer selected from the group consisting of carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, and melanoma.

52. The method of claim 51 , wherein the cancer is selected from the group consisting of adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma's, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus carcinoma, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinomas, uterine cancer, cervical cancer, neck, nose and ear tumors, hematological neoplasia's, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinoma, craniopharyngeoma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, stomach cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer and lymph gland cancer.

53. A method for treating a patient suffering from a disease selected from the group consisting of a cancer, a virus disease, autoimmune disease, acute or chronic inflammatory disease, and a disease caused by bacteria, fungi, and other micro-organisms, comprising administering to the patient a therapeutically effective amount of the compound according to claim 10 or the pharmaceutical composition according to claim 49 .

54. The method of claim 53 , wherein the disease is cancer selected from the group consisting of carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, and melanoma.

55. The method of claim 54 , wherein the cancer is selected from the group consisting of adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma's, basalioma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus carcinoma, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial carcinoma, gallbladder cancer, gallbladder carcinomas, uterine cancer, cervical cancer, neck, nose and ear tumors, hematological neoplasia's, hairy cell leukemia, urethral cancer, skin cancer, gliomas, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal carcinoma, head/neck tumors, colon carcinoma, craniopharyngeoma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, stomach cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, penile cancer, prostate cancer, tongue cancer and lymph gland cancer.